X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Manufacturing

FDA Officials Support Moderna, Pfizer COVID-19 Jabs For Kids

Content Team by Content Team
15th June 2022
in Manufacturing, Middle East and South Asia, News
Qatar approves emergency use of Modernas COVID-19 vaccine

Parents may soon be allowed to line up their children for vaccinations after Pfizer and Moderna’s COVID-19 vaccine application for young children progresses through the FDA’s regulatory procedure. Independent experts will vote this week as to whether to recommend Moderna’s vaccine for a broad range of children and teens and Pfizer’s vaccine for children aged 6 months to 4 years.

The FDA officials released their own conclusions ahead of the conference, stating that the immunizations are typically effective and safe in the relevant age groups. According to the reviewers, data from Pfizer’s programme revealed that the major sequence was 75.6% effective in children aged 6 months to 23 months. Efficacy was 82.4% in the 2- to 4-year-old age group. Gentleness at the injection site, irritability, sleepiness, decreased appetite, and fever were the most common adverse events in the 6-23 month group. The FDA staff stated that the rates of adverse responses for those participants were less than those in the 5-to-11-year-old age group.

Adverse effects in the 2- to 4-year-old age group included soreness at the injection site, weariness, headache, and cold. The rates were also lower than in the 5-to 11-year-old age group. An analysis indicated that the vaccination evokes equal production of antibodies against delta and the reference strain, but substantially lower levels against omicron, in response to the FDA’s demand for further information on the vaccine’s efficacy against the delta and omicron variations.

Moderna’s programme is unique in that the vaccine is not currently approved for adolescents, therefore the company is submitting two distinct applications for children aged 6 months to 17 years- one for children aged 6 months to 5 years and another one for children aged 6 years to 17 years.

Vaccine efficacy for children aged 12 to 17 years was 93.3% in trials, which is similar to the efficacy found in the adult study. The effectiveness rate was 76.8% in the 6-to 11-year-old group. According to FDA officials, the Moderna tests were completed during the omicron spike, and performance for this version looked to be consistent with efficacy reported in adults during the surge.

Meanwhile, adopting the CDC case definition, effectiveness in the 2-to 5-year-old group was lower, at 36.8%. Finally, efficacy was 50.6% in the 6-to-23-month group, according to the CDC definition.

Injection site pain was the most prevalent reaction after getting a dose, trailed by headaches and exhaustion. Other side effects were similar to those seen with the placebo. Another common and long-lasting reaction was irritability or crying. According to the CDC, COVID-19 has caused approximately 533 million illnesses and 6.3 million deaths worldwide. The Biden administration has stated that if the FDA approves the children’s immunizations, shots may begin in arms by June 21.

Previous Post

FDA Not So Fast On Approval Of The Novavax COVID-19 Vaccine

Next Post

Kymriah Data Shows Sustained Remission In Kids, Young Adults

Related Posts

Kymriah Data Shows Sustained Remission In Kids, Young Adults
Manufacturing

Kymriah Data Shows Sustained Remission In Kids, Young Adults

15th June 2022
Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations
Manufacturing

FDA Not So Fast On Approval Of The Novavax COVID-19 Vaccine

14th June 2022
FDA Rebukes Althera On Cholesterol Medication Assertions
Manufacturing

FDA Rebukes Althera On Cholesterol Medication Assertions

14th June 2022
Seqirus, North Carolina Gets Fill Finish Expansion of $156mn
Manufacturing

Seqirus, North Carolina Gets Fill Finish Expansion of $156mn

14th June 2022
Manufacturing

GARDP Helps Bugworks Assess New Antibiotics Effectiveness

14th June 2022
ACHEMA 2022 addresses the industry's key issues digitalisation and sustainability
Manufacturing

ACHEMA 2022 addresses the industry’s key issues digitalisation and sustainability

14th June 2022
Next Post
Kymriah Data Shows Sustained Remission In Kids, Young Adults

Kymriah Data Shows Sustained Remission In Kids, Young Adults

Latest News

Kymriah Data Shows Sustained Remission In Kids, Young Adults
Manufacturing

Kymriah Data Shows Sustained Remission In Kids, Young Adults

15th June 2022
Qatar approves emergency use of Modernas COVID-19 vaccine
Manufacturing

FDA Officials Support Moderna, Pfizer COVID-19 Jabs For Kids

15th June 2022
Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations
Manufacturing

FDA Not So Fast On Approval Of The Novavax COVID-19 Vaccine

14th June 2022
FDA Rebukes Althera On Cholesterol Medication Assertions
Manufacturing

FDA Rebukes Althera On Cholesterol Medication Assertions

14th June 2022
Seqirus, North Carolina Gets Fill Finish Expansion of $156mn
Manufacturing

Seqirus, North Carolina Gets Fill Finish Expansion of $156mn

14th June 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In